Get notified when VVOS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: VVOS Vivos Therapeutics, Inc. 8-K

Vivos raises $2.25M from affiliate investor, converting debt and issuing warrants for 3.6M shares

Filed April 3, 2026 · Period ending April 3, 2026 · ~1 min read

Key Changes

  • high

    Company received $850K cash and converted $1.4M bridge debt into equity via private placement to V-Co 3, an affiliate of existing investor Seneca. Total proceeds of $2.25M designated for working capital.

  • high

    Issued 1.35M common shares plus pre-funded warrant for 430K shares (exercisable at $0.0001), and two warrant series each for 1.78M shares at $1.09 exercise price. Full exercise would add 4M shares beyond initial issuance.

  • high

    Series A warrants expire in 2 years, Series B in 5 years, both immediately exercisable at $1.09 per share. Warrants include anti-dilution protection and cap Seneca ownership at 19.99% of outstanding stock.

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.

Partner

Trade VVOS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify